top of page


Post-stroke muscle disorders (PSMD) is a complex phenomenon (ie. muscle weakness, fibrosis, atrophy, dystonia, abnormal reflex response, pain), and is a cause of long term disability and emotional distress. 


Post-stroke spasticity (PSS) is known to impact one in four stroke patients and is induced by the dissociation or disintegration of motor responses from sensory input, leading to hyperexcitability of the segmental central nervous system (CNS), correlating with sensory input intensity and CNS lesion location.


Current interventions to address PSMD and PSS include: Physical and occupational therapy, mobility assistive devices, TENS, pharmacogenics, alternative therapy, robotic therapy, orthopedic and neurosurgery, but remains a clinical challenge to manage.

The rationale for the use of Flashwave® for patients suffering from PAMD and PSS is due to the safety and mechanics of action of Flashwave®, known to assist in tissue regeneration addressing the atrophy and fibrosis associated with this condition.

Furthermore the influence of Flashwave® on neurotransmitters could assist in playing an integral part of reorganizing synaptic plasticity and help rejuvenate motion memory loss due to this syndrome. The use of Flashwave® in cases such as this is to introduce a ‘bottom-up’ reflex loop where peripheral biocellular transduction communicates with CNS structures to help induce motor - neuron - function in affected regions.

The regenerative capacity provided by Flashwave® will assist other rehabilitation functions such as physical activity, further enhancing the overall recovery and functional prognosis of PAMD and PSS patients.

bottom of page